West Pharmaceutical Services, Inc. — Cyborg Score 8/10

Strategic Profile

With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West delivers over 41 billion components and devices each year. The company's High-Value Product Components business, including Westar and Envision products, showed strong organic growth of 15.1% in Q4 2025.

Cyborg Score Rationale

West reported 2025 full-year sales of $3.07 billion with net income of $493.7 million and adjusted EPS of $7.29 representing 8% growth. For 2026, the company projects 5-7% organic growth and adjusted EPS growth of 7.7-12.5%. Operating margin stands at 20.9% with net margin of 16.29%, indicating efficient cost management.

Top Insights

• High-Value Product Components grew 15.1% organically in Q4 2025, driven by strength in Westar and Envision products.
• Organic net sales growth is expected to outpace reported growth, with the planned sale of SmartDose 3.5ml to AbbVie mid-year becoming a key driver.
• Operating margin of 20.9% and debt-to-equity ratio of 0.1 indicate strong profitability and minimal financial leverage.
• Q4 reported EPS of $2.04 beat consensus by $0.21 with a net margin of 16.29% and return on equity of 18.16%.

Named Competitors

• Syringes & Cartridges — Medical device manufacturer with injectable systems
• Injectable Components — Glass and plastic pharmaceutical packaging solutions
• Drug Delivery Systems — Pharmaceutical packaging and drug delivery systems

Recent Developments

• (February 2026) Q4 2025 earnings beat expectations with revenue of $805M (up 7.5% YoY) and EPS of $2.04
• (February 2026) Issued 2026 guidance of $3.215-3.275B revenue and $7.85-8.20 EPS with 5-7% organic growth
• (Mid-2026) Planned sale of SmartDose 3.5ml platform to AbbVie for $55M in H2 2025 revenues

Open the full interactive West Pharmaceutical Services, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.